

1 Jane M Love, Ph.D. (*pro hac vice* to be filed)  
2 (NY Bar No. 3016995)  
3 *jlove@gibsondunn.com*  
4 Robert W. Trenchard (*pro hac vice* to be filed)  
5 (NY Bar No. 2679488)  
6 *rtrenchard@gibsondunn.com*  
7 GIBSON, DUNN & CRUTCHER LLP  
200 Park Ave  
New York, NY 10166  
Telephone: 212.351.4000  
Facsimile: 212.351.4035

Y. Ernest Hsin  
(CA Bar No. 201668)  
*ehsin@gibsondunn.com*  
GIBSON, DUNN & CRUTCHER LLP  
555 Mission Street  
San Francisco, CA 94105  
Telephone: 415.393.8200  
Facsimile: 415.393.8306

8 Christine L. Ranney  
9 (CA Bar No. 295773)  
10 *cranney@gibsondunn.com*  
11 GIBSON, DUNN & CRUTCHER LLP  
12 1801 California St.  
Denver, CO 80202  
Telephone: 303.298.5700  
Facsimile: 303.298.5907

13 *Attorneys for Plaintiff*  
14 *Novartis Pharmaceuticals Corporation*

15 **UNITED STATES DISTRICT COURT**  
16 **NORTHERN DISTRICT OF CALIFORNIA**

17 NOVARTIS PHARMACEUTICALS  
CORPORATION,

18 Plaintiff,

19 v.

20 HANDA NEUROSCIENCE, LLC, HANDA  
21 PHARMACEUTICALS, INC., HANDA  
22 PHARMA, INC., and HANDA  
PHARMACEUTICALS, LLC,

23 Defendants.

Case No. 3:21-cv-03397

**COMPLAINT FOR PATENT  
INFRINGEMENT**

1 Novartis Pharmaceuticals Corporation (“Novartis”) by its attorneys hereby alleges as follows:

2 **NATURE OF THE ACTION**

3 1. This is an action for patent infringement arising under the patent laws of the United  
4 States, Title 35, United States Code and for declaratory judgment pursuant to the Declaratory Judgment  
5 Act, 28 U.S.C §§ 2201, *et seq.* This action relates to a New Drug Application (“NDA”) filed under 21  
6 U.S.C. § 355(b)(2) by the above-named defendants (collectively, “Handa”) with the U.S. Food and  
7 Drug Administration (“FDA”) for approval to engage in the commercial manufacture, use, or sale of  
8 Fingolimod Orally Disintegrating Tablets 0.5 mg, a version of Novartis’s GILENYA® Capsules, 0.5  
9 mg, prior to expiration of U.S. Patent Nos. 9,187,405 (“the ’405 patent”) and 10,543,179 (“the ’179  
10 patent”).

11 **PARTIES**

12 2. Novartis Pharmaceuticals Corporation is a corporation organized and existing under the  
13 laws of the State of Delaware, with its principal place of business in East Hanover, New Jersey.

14 3. Upon information and belief, Defendant Handa Pharmaceuticals, Inc. is a corporation  
15 organized and existing under the laws of Taiwan, having a principal place of business at 3F-1&3F-2,  
16 No.23, Nanke 3rd Rd., Tainan City 74147, Taiwan.

17 4. Upon information and belief, Defendant Handa Pharma, Inc. is a corporation organized  
18 and existing under the laws of Delaware, having a principal place of business at 1732 N. First Street,  
19 Suite 200 San Jose, California 95112. Upon information and belief, Handa Pharma, Inc. is a wholly-  
20 owned subsidiary of Handa Pharmaceuticals, Inc.

21 5. Upon information and belief, Defendant Handa Pharmaceuticals, LLC is a limited  
22 liability company organized and existing under the laws of Delaware, having a principal place of  
23 business at 1732 N. First Street, Suite 200 San Jose, California 95112. Upon information and belief,  
24 Handa Pharmaceuticals, LLC is a wholly-owned subsidiary of Handa Pharma, Inc.

25 6. Upon information and belief, Defendant Handa Neuroscience, LLC is a limited liability  
26 company organized and existing under the laws of California, having a principal place of business at  
27 1732 N. First Street, Suite 200 San Jose, California 95112. Upon information and belief, Handa  
28 Neuroscience, LLC is a wholly-owned subsidiary of Handa Pharma, Inc.

1           7.       Handa notified Plaintiff that Handa had, under § 505(b)(2) of the Federal Food, Drug,  
2 and Cosmetic Act (“FDCA”) (21 U.S.C. § 355(b)(2)), submitted to FDA NDA No. 214962 (“the  
3 505(b)(2) NDA”) for Fingolimod Orally Disintegrating Tablets 0.5 mg, a drug product that is a version  
4 of GILENYA<sup>®</sup> (“the 505(b)(2) Product”). The purpose of Handa’s submission of the 505(b)(2) NDA  
5 was to obtain approval under the FDCA to engage in the commercial manufacture, use, offer for sale,  
6 and/or sale of Handa’s 505(b)(2) NDA Product prior to the expiration of the ’405 and ’179 patents.

7           8.       Handa notified Plaintiff that, as a part of its 505(b)(2) NDA, Handa had filed a  
8 certification of the type described in Section 505(b)(2)(A)(iv) of the FDCA (21 U.S.C. §  
9 355(b)(2)(A)(iv)) with respect to the ’405 and ’179 patents asserting that both patents are invalid,  
10 unenforceable, and/or will not be infringed by the commercial manufacture, use, and sale of Handa’s  
11 505(b)(2) NDA Product.

12           9.       Handa has committed an act of infringement in this judicial district by filing NDA No.  
13 214962 with the intent to make, use, offer to sell, and/or sell the drug products that are the subject of  
14 NDA No. 214962, which has led to foreseeable harm and injury to Novartis.

15           10.      Upon information and belief, Handa Pharmaceuticals, Inc., Handa Pharma, Inc., Handa  
16 Pharmaceuticals, LLC, and Handa Neuroscience, LLC acted collaboratively in the preparation and  
17 submission of NDA No. 214962 and upon information and belief will work in concert with one another  
18 to make, use, offer to sell, and/or sell the drug products that are the subject of NDA No. 214962  
19 throughout the United States, and/or import such drug products into the United States, including in this  
20 judicial district.

21           11.      Upon information and belief, Handa’s overall business strategy comprises utilizing its  
22 Taiwan headquarters as its global R&D center and establishing its presence in the U.S. market through  
23 its U.S. subsidiaries.

24           12.      Upon information and belief, Handa Pharmaceuticals, Inc. is Handa’s headquarters and  
25 global research and development center; Handa Pharma, Inc. is responsible for business development,  
26 intellectual property, and regulatory affairs; Handa Pharmaceuticals, LLC is responsible for Generics  
27 Business; and Handa Neuroscience, LLC is responsible for Brand Products – Neuroscience.

28

1 13. Upon information and belief, Handa Pharma, Inc., Handa Pharmaceuticals, LLC, and  
2 Handa Neuroscience, LLC (“the Handa US Entities”) share an office in San Jose, California.

3 14. Upon information and belief, Dr. Fangyu Liu is the founder, President, and Chairman  
4 of the Board of Directors of Handa Pharmaceuticals, Inc. Upon information and belief, Dr. Liu is also  
5 the President of Handa Pharma, Inc., the Manager of Handa Pharmaceuticals, LLC, and the CEO and  
6 agent for the service of process of Handa Neuroscience LLC.

7 15. Upon information and belief, Dr. Liu is the sole inventor listed on U.S. Patent Nos.  
8 9,925,138, 10,555,902, and 10,925,829 (“Liu Patents”).

9 16. Upon information and belief, the Liu Patents are directed to subject matter related to  
10 Handa’s 505(b)(2) NDA Product.

11 17. Upon information and belief, Handa refers to its 505(b)(2) NDA Product as “HND-  
12 020,” an orally disintegrating tablet indicated for Multiple Sclerosis. Upon information and belief,  
13 Handa Pharmaceuticals, Inc. first successfully manufactured a pilot batch of its 505(b)(2) NDA Product  
14 in 2018.

15 18. Upon information and belief, in October 2019, Dr. Liu assigned the Liu Patents to  
16 Handa Pharmaceuticals, LLC.

17 19. Upon information and belief, Handa Neuroscience, LLC was incorporated on July 17,  
18 2020.

19 20. Upon information and belief, in August 2020, Handa Pharmaceuticals, LLC assigned  
20 the Liu Patents to Handa Neuroscience, LLC.

21 21. Upon information and belief, Handa submitted its 505(b)(2) NDA to FDA on December  
22 18, 2020. Handa indicated in its notice to Novartis that Handa Neuroscience, LLC is the sponsor of  
23 NDA No. 214962, Handa’s 505(b)(2) NDA.

24 22. Upon information and belief, Handa Neuroscience, LLC acted as an agent for and at the  
25 direction and control of Handa Pharmaceuticals, Inc., including through its other agents Handa Pharma,  
26 Inc. and Handa Pharmaceuticals, LLC, in submitting the 505(b)(2) NDA to FDA.

1 23. Upon information and belief, Handa Pharmaceuticals, Inc. dominates and controls the  
2 affairs of the Handa US Entities such that the Handa US Entities are alter egos of Handa  
3 Pharmaceuticals, Inc.

4 24. Upon information and belief, Handa Pharmaceuticals, Inc. has extensive contacts with  
5 the State of California, including through its subsidiaries Handa Pharma, Inc., Handa Pharmaceuticals,  
6 LLC, and Handa Neuroscience, LLC and regularly does business in this District, including through its  
7 subsidiaries Handa Pharma, Inc., Handa Pharmaceuticals, LLC, and Handa Neuroscience, LLC.

8 25. Handa Pharmaceuticals, Inc. has availed itself of the legal protections of the State of  
9 California by, among other things, selecting the State of California as the place of incorporation for  
10 Handa Neuroscience, LLC.

11 26. Upon information and belief, Handa Pharma, Inc. is headquartered in this District, has  
12 extensive contacts with the State of California, including through its subsidiaries Handa  
13 Pharmaceuticals, LLC and Handa Neuroscience, LLC, and regularly does business in this District,  
14 including through its subsidiaries Handa Pharmaceuticals, LLC and Handa Neuroscience, LLC.

15 27. Upon information and belief, Handa Pharmaceuticals, LLC is headquartered in this  
16 District, has extensive contacts with the State of California, and regularly does business in this District.

17 28. Upon information and belief, Handa Neuroscience, LLC is headquartered in this  
18 District, has extensive contacts with the State of California, and regularly does business in this District.

19 **JURISDICTION AND VENUE**

20 29. This action arises under the patent laws of the United States, 35 U.S.C. §§ 100, *et seq.*,  
21 and this Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331 and  
22 1338(a). Venue is proper in this Court under 28 U.S.C. §§ 1391 and 1400(b).

23 30. This Court has personal jurisdiction over each Defendant because, among other things,  
24 each has committed, induced, or aided, abetted, contributed to, or participated in the commission of,  
25 tortious acts of patent infringement in in this district by filing the 505(b)(2) NDA with intent to  
26 commercially manufacture, use, offer for sale, sell, market, distribute, and/or import its 505(b)(2) NDA  
27 Product in the State of California, including in this District.

31. This Court also has personal jurisdiction over each Defendant because each of each of the Defendants' affiliations with the State of California, including by virtue of Handa Pharma, Inc., Handa Pharmaceuticals, LLC, and Handa Neuroscience, LLC having their principal place of business in this District and Handa Neuroscience, LLC being organized under the laws of the State of California, are so continuous and systematic as to render each Defendant essentially at home in this forum.

32. For these reasons, and for other reasons that will be presented to the Court if jurisdiction is challenged, the Court has personal jurisdiction over each Defendant.

33. Venue is proper in this Court under both 28 U.S.C. § 1400(b) and 28 U.S.C. § 1391 because, *inter alia*, each Handa US Entity is organized under the laws of the State of California and/or has its principal place of business in this District and therefore "resides" in this judicial district, and/or has committed acts of infringement in this District and has a regular and established place of business in this District. Handa Pharmaceuticals, Inc. is a foreign corporation not residing in any United States judicial district and may be sued in any judicial district. 28 U.S.C. § 1391(c)(3).

#### GILENYA®

34. Novartis is the holder of New Drug Application ("NDA") No. 022527 by which the FDA granted approval for the commercial manufacturing, marketing, sale, and use of GILENYA® (fingolimod) Capsules, 0.5 mg. GILENYA® is the first in a new class of compounds known as sphingosine 1-phosphate receptor (S1PR) modulators. GILENYA® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. GILENYA® is the first oral drug that has been approved by the FDA for such an indication.

#### THE PATENTS-IN-SUIT

35. On November 17, 2015, the U.S. Patent and Trademark Office duly and legally issued the '405 patent, entitled "S1P Receptor Modulators for Treating Relapsing[*sic*]-Remitting Multiple Sclerosis." A true and correct copy of the '405 patent is attached hereto as **Exhibit A**.

36. Claim 1 of the '405 patent recites: "A method for reducing or preventing or alleviating relapses in Relapsing-Remitting multiple sclerosis in a subject in need thereof, comprising orally administering to said subject [fingolimod], in free form or in a pharmaceutically acceptable salt form,

1 at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen.” Independent  
2 claims 3 and 5 are similar to claim 1 but recite methods for “treating Relapsing-Remitting multiple  
3 sclerosis” and “slowing progression of Relapsing-Remitting multiple sclerosis” in subjects in need  
4 thereof. Dependent claims 2, 4, and 6 recite the further limitation that fingolimod hydrochloride is  
5 administered.

6 37. The claims of the '405 patent are neither invalid nor unenforceable, as held by the  
7 United States District Court for the District of Delaware in a final judgment dated September 11, 2020  
8 (*Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc.*, C.A. No. 18-1043-KAJ, D.I. 780  
9 (D. Del.)), and as previously held by the United States Patent and Trademark Office in its Final Written  
10 Decision following *inter partes* review. *See Apotex Inc. v. Novartis A.G.*, IPR2017-00854, 2018 WL  
11 3414289 (P.T.A.B. July 11, 2018). The '405 patent is wholly owned by Novartis, which therefore has  
12 the right to sue for and obtain equitable relief and damages for infringement of the '405 patent.

13 38. GILENYA<sup>®</sup> and the use of GILENYA<sup>®</sup> is covered by one or more claims of the '405  
14 patent.

15 39. The FDA's official publication of approved drugs (the “Orange Book”) lists the '405  
16 patent in connection with GILENYA<sup>®</sup>.

17 40. On January 28, 2020, the U.S. Patent and Trademark Office duly and legally issued the  
18 '179 patent, entitled “Dosage Regimen of an S1P Receptor Modulator.” A true and correct copy of the  
19 '179 patent is attached hereto as **Exhibit B**.

20 41. Claim 1 of the '179 patent recites: “A method for treating relapsing remitting multiple  
21 sclerosis in a patient in need thereof, the method comprising: (a) identifying a patient at risk of  
22 contracting infection caused by varicella zoster virus by testing said patient for a history of infection  
23 caused by varicella zoster virus, (b) vaccinating the patient at risk of contracting infection caused by  
24 varicella zoster virus, and (c) administering orally fingolimod or a pharmaceutically acceptable salt  
25 thereof to said patient at a daily dosage of 0.5 mg.” Claims 2, 3, and 4, which each depend from claim  
26 1, recite further limitations: that “treating comprises reducing the frequency of clinical exacerbations”;  
27 that “fingolimod is administered as a hydrochloride salt”; and that “the infection is chickenpox.”  
28

1 42. The claims of the '179 patent are neither invalid nor unenforceable. The '179 patent is  
2 wholly owned by Novartis, which therefore has the right to sue for and obtain equitable relief and  
3 damages for infringement of the '179 patent.

4 43. GILENYA<sup>®</sup> and the use of GILENYA<sup>®</sup> is covered by one or more claims of the '179  
5 patent.

6 44. The FDA's official publication of approved drugs (the "Orange Book") lists the '179  
7 patent in connection with GILENYA<sup>®</sup>.

8 **COUNT I: INFRINGEMENT BY EACH DEFENDANT OF THE '405 PATENT UNDER 35**

9 **U.S.C. § 271(e)**

10 45. Plaintiff incorporates each of the preceding paragraphs 1 – 44 as if fully set forth herein.

11 46. Handa has notified Novartis of its intent to engage in the commercial manufacture, use,  
12 offer for sale, sale, marketing, distributing, and/or importation of its 505(b)(2) NDA Product prior to  
13 the expiration of the '405 patent.

14 47. Handa's 505(b)(2) NDA submission seeking approval to engage in the commercial  
15 manufacture, use, offer to sell, or sale of its 505(b)(2) NDA Product, prior to the expiration of the '405  
16 patent constitutes infringement of one or more of the claims of the '405 patent under 35 U.S.C.  
17 § 271(e)(2)(A).

18 48. Upon information and belief, Handa intends to engage in the commercial manufacture,  
19 use, offer for sale, sale, marketing, distributing, and/or importation of its 505(b)(2) NDA Product with  
20 its proposed labeling immediately and imminently upon final approval of its 505(b)(2) NDA.

21 49. Handa, by filing its 505(b)(2) NDA, has represented to the FDA that, upon approval, its  
22 505(b)(2) NDA Product will have the same active ingredient or a pharmaceutically acceptable salt  
23 thereof and dosage amount as GILENYA<sup>®</sup>, and will be bioequivalent to GILENYA<sup>®</sup>. Specifically,  
24 Handa has indicated to Novartis that its 505(b)(2) NDA Product contains the same drug in the same  
25 dosage amount as GILENYA<sup>®</sup>, and that Handa's 505(b)(2) NDA contains the bioavailability and/or  
26 bioequivalence data and information from studies of Handa's 505(b)(2) NDA Product.

27 50. Handa has indicated that its 505(b)(2) NDA Product is orally administered and contains  
28 0.5 mg fingolimod.



1           51.     FDA regulations require that Handa’s 505(b)(2) NDA Product labeling instruct that its  
2     505(b)(2) NDA Product be administered for approved indications at approved dosages. *See* 21 U.S.C.  
3     § 355(d) (setting forth that FDA may reject an NDA that does not contain reports showing “adequate  
4     tests by all methods reasonably applicable to show whether or not [the] drug is safe for use under the  
5     conditions prescribed, recommended, or suggested in the proposed labeling thereof”); 21 C.F.R. §  
6     201.57(c)(2)(iv) (requiring that “all indications listed in [the Indications and Usage] section [of the  
7     drug labeling] must be supported by substantial evidence of effectiveness based on adequate and well-  
8     controlled studies as defined in § 314.126(b),” where § 314.126(b) provides placebo concurrent control,  
9     dose-comparison concurrent control, and active treatment concurrent control as examples).

10           52.     Upon information and belief, the only FDA-approved indication for fingolimod, and the  
11     only indication adequately supported by adequate tests and studies, is the same as that of Novartis’s  
12     GILENYA<sup>®</sup> product and that recited in at least claim 1 of the ’405 patent, specifically the treatment of  
13     relapsing-remitting multiple sclerosis, including by “reducing or preventing or alleviating relapses.”

14           53.     Upon information and belief, FDA has not approved for any indication the  
15     administration of fingolimod at a dose higher than 0.5 mg orally once daily, and therefore Handa’s  
16     label will indicate that Handa’s 505(b)(2) NDA product should be administered “absent an immediately  
17     preceding loading dose.”

18           54.     Thus, upon information and belief, Handa’s 505(b)(2) NDA Product labeling will  
19     disclose all elements of at least claim 1 of the ’405 patent, therefore showing that use by, for example,  
20     patients and/or healthcare providers of Handa’s 505(b)(2) NDA Product in accordance with its  
21     proposed labeling will infringe at least claim 1 of the ’405 patent.

22           55.     Upon information and belief, Handa’s 505(b)(2) NDA Product’s proposed labeling will  
23     instruct, for example, patients and/or healthcare providers to perform all elements of at least claim 1 of  
24     the ’405 patent.

25           56.     The commercial manufacture, use, offer for sale, sale, marketing, distributing, and/or  
26     importation of Handa’s 505(b)(2) NDA Product would infringe one or more claims of the ’405 patent.

27           57.     Upon information and belief, use of Handa’s 505(b)(2) NDA Product in accordance  
28     with and as directed by its proposed labeling would infringe one or more claims of the ’405 patent.

1           58.     Upon information and belief, Handa will have actual knowledge of the '405 patent and  
2 will actively induce infringement of the '405 patent when its 505(b)(2) NDA is approved, and will do  
3 so immediately and imminently upon final approval.

4           59.     Upon information and belief, Handa will know that its 505(b)(2) NDA Product is  
5 especially made or adapted for use in infringing the '405 patent, and that its 505(b)(2) NDA Product is  
6 not suitable for any substantial non-infringing use. Upon information and belief, Handa will contribute  
7 to the infringement of the '405 patent immediately and imminently upon approval of its 505(b)(2)  
8 NDA.

9           60.     The foregoing acts by Handa constitute and/or will constitute active inducement of  
10 infringement of the '405 patent and/or contribution to the infringement by others of the '405 patent  
11 under 35 U.S.C. §§ 271(b) and (c).

12           61.     If Handa's infringement of the '405 patent is not permanently enjoined, Plaintiff will  
13 suffer substantial and irreparable harm for which there is no remedy at law.

14     **COUNT II: DECLARATORY JUDGMENT OF INFRINGEMENT BY EACH DEFENDANT**  
15                     **OF THE '405 PATENT UNDER 35 U.S.C. §§ 271(b) AND (c)**

16           62.     Plaintiff incorporates each of the preceding paragraphs 1 – 61 as if fully set forth herein.

17           63.     Upon information and belief, Handa intends to engage in the commercial manufacture,  
18 use, offer for sale, sale, marketing, distributing, and/or importation of its 505(b)(2) NDA Product with  
19 its proposed labeling immediately and imminently upon final approval of its 505(b)(2) NDA.  
20 Therefore a case or controversy exists between each Defendant or group of Defendants and Novartis  
21 as to infringement of the '405 patent.

22           64.     Handa, by filing its 505(b)(2) NDA, has represented to the FDA that, upon approval, its  
23 505(b)(2) NDA Product will have the same active ingredient or a pharmaceutically acceptable salt  
24 thereof and dosage amount as GILENYA<sup>®</sup>, and will be bioequivalent to GILENYA<sup>®</sup>. Specifically,  
25 Handa has indicated to Novartis that its 505(b)(2) NDA Product contains the same drug in the same  
26 dosage amount as GILENYA<sup>®</sup>, and that Handa's 505(b)(2) NDA contains the bioavailability and/or  
27 bioequivalence data and information from studies of Handa's 505(b)(2) NDA Product.

1           65.     Handa has indicated that its 505(b)(2) NDA Product is orally administered and contains  
2 0.5 mg fingolimod.

3           66.     FDA regulations require that Handa’s 505(b)(2) NDA Product labeling instruct that its  
4 505(b)(2) NDA Product be administered for approved indications at approved dosages. *See* 21 U.S.C.  
5 § 355(d) (setting forth that FDA may reject an NDA that does not contain reports showing “adequate  
6 tests by all methods reasonably applicable to show whether or not [the] drug is safe for use under the  
7 conditions prescribed, recommended, or suggested in the proposed labeling thereof”); 21 C.F.R. §  
8 201.57(c)(2)(iv) (requiring that “all indications listed in [the Indications and Usage] section [of the  
9 drug labeling] must be supported by substantial evidence of effectiveness based on adequate and well-  
10 controlled studies as defined in § 314.126(b),” where § 314.126(b) provides placebo concurrent control,  
11 dose-comparison concurrent control, and active treatment concurrent control as examples).

12           67.     Upon information and belief, the only FDA-approved indication for fingolimod, and the  
13 only indication adequately supported by adequate tests and studies, is the same as that of Novartis’s  
14 GILENYA<sup>®</sup> product and that recited in at least claim 1 of the ’405 patent, specifically the treatment of  
15 relapsing-remitting multiple sclerosis, including by “reducing or preventing or alleviating relapses.”

16           68.     Upon information and belief, FDA has not approved for any indication the  
17 administration of fingolimod at a dose higher than 0.5 mg orally once daily, and therefore Handa’s  
18 label will indicate that Handa’s 505(b)(2) NDA product should be administered “absent an immediately  
19 preceding loading dose.”

20           69.     Thus, upon information and belief, Handa’s 505(b)(2) NDA Product labeling will  
21 disclose all elements of at least claim 1 of the ’405 patent, therefore showing that use by, for example,  
22 patients and/or healthcare providers of Handa’s 505(b)(2) NDA Product in accordance with its  
23 proposed labeling will infringe at least claim 1 of the ’405 patent.

24           70.     Upon information and belief, Handa’s 505(b)(2) NDA Product’s proposed labeling will  
25 instruct, for example, patients and/or healthcare providers to perform all elements of at least claim 1 of  
26 the ’405 patent.

27           71.     The commercial manufacture, use, offer for sale, sale, marketing, distributing, and/or  
28 importation of Handa’s 505(b)(2) NDA Product would infringe one or more claims of the ’405 patent.

1           72. Upon information and belief, use of Handa's 505(b)(2) NDA Product in accordance  
2 with and as directed by its proposed labeling would infringe one or more claims of the '405 patent.

3           73. Upon information and belief, Handa will have actual knowledge of the '405 patent and  
4 will actively induce infringement of the '405 patent when its 505(b)(2) NDA is approved, and will do  
5 so immediately and imminently upon final approval.

6           74. Upon information and belief, Handa will know that its 505(b)(2) NDA Product is  
7 especially made or adapted for use in infringing the '405 patent, and that its 505(b)(2) NDA Product is  
8 not suitable for any substantial non-infringing use. Upon information and belief, Handa will contribute  
9 to the infringement of the '405 patent immediately and imminently upon approval of its 505(b)(2)  
10 NDA.

11           75. The foregoing acts by Handa constitute and/or will constitute active inducement of  
12 infringement of the '405 patent and/or contribution to the infringement by others of the '405 patent  
13 under 35 U.S.C. §§ 271(b) and (c).

14           76. If Handa's infringement of the '405 patent is not permanently enjoined, Plaintiff will  
15 suffer substantial and irreparable harm for which there is no remedy at law.

16 **COUNT III: INFRINGEMENT BY EACH DEFENDANT OF THE '179 PATENT UNDER 35**

17 **U.S.C. § 271(e)**

18           77. Plaintiff incorporates each of the preceding paragraphs 1 – 76 as if fully set forth herein.

19           78. Handa has notified Novartis of its intent to engage in the commercial manufacture, use,  
20 offer for sale, sale, marketing, distributing, and/or importation of its 505(b)(2) NDA Product prior to  
21 the expiration of the '179 patent.

22           79. Handa's 505(b)(2) NDA submission seeking approval to engage in the commercial  
23 manufacture, use, offer to sell, or sale of its 505(b)(2) NDA Product, prior to the expiration of the '179  
24 patent constitutes infringement of one or more of the claims of the '179 patent under 35 U.S.C.  
25 § 271(e)(2)(A).

26           80. Upon information and belief, Handa intends to engage in the commercial manufacture,  
27 use, offer for sale, sale, marketing, distributing, and/or importation of its 505(b)(2) NDA Product with  
28 its proposed labeling immediately and imminently upon final approval of its 505(b)(2) NDA.

1           81.     Handa, by filing its 505(b)(2) NDA, has represented to the FDA that, upon approval, its  
2     505(b)(2) NDA Product will have the same active ingredient or a pharmaceutically acceptable salt  
3     thereof and dosage amount as GILENYA<sup>®</sup>, and will be bioequivalent to GILENYA<sup>®</sup>. Specifically,  
4     Handa has indicated to Novartis that its 505(b)(2) NDA Product contains the same drug in the same  
5     dosage amount as GILENYA<sup>®</sup>, and that Handa's 505(b)(2) NDA contains the bioavailability and/or  
6     bioequivalence data and information from studies of Handa's 505(b)(2) NDA Product.

7           82.     Handa has indicated that its 505(b)(2) NDA Product is orally administered and contains  
8     0.5 mg fingolimod.

9           83.     FDA regulations require that Handa's 505(b)(2) NDA Product labeling contain safety  
10    information associated with its 505(b)(2) NDA Product. *See* 21 C.F.R. 201.56(a)(1) ("The labeling  
11    must contain a summary of the essential scientific information needed for the safe and effective use of  
12    the drug."); 21 C.F.R. 201.57(c)(6) (requiring under "Warnings and precautions" a description of  
13    "clinically significant adverse reactions (including any that are potentially fatal, are serious even if  
14    infrequent, or can be prevented or mitigated through appropriate use of the drug), other potential safety  
15    hazards [], limitations in use imposed by them [], and steps that should be taken if they occur[.]")

16          84.     As reflected in the GILENYA<sup>®</sup> label (attached hereto as **Exhibit C**) under the heading  
17    "WARNINGS AND PRECAUTIONS" and further under the heading "Infections," FDA has required  
18    instruction that "[p]atients without a healthcare professional confirmed history of chickenpox or  
19    without documentation of a full course of vaccination against VZV should be tested for antibodies to  
20    VZV before initiating GILENYA" and furthermore that "VZV vaccination of antibody-negative  
21    patients is recommended prior to commencing treatment with GILENYA." Upon information and  
22    belief, Handa's 505(b)(2) NDA proposed labeling contains an identical or substantially similar  
23    instruction.

24          85.     FDA regulations require that Handa's 505(b)(2) NDA Product labeling instruct that its  
25    505(b)(2) NDA Product be administered for approved indications at approved dosages. *See* 21 U.S.C.  
26    § 355(d) (setting forth that FDA may reject an NDA that does not contain reports showing "adequate  
27    tests by all methods reasonably applicable to show whether or not [the] drug is safe for use under the  
28    conditions prescribed, recommended, or suggested in the proposed labeling thereof"); 21 C.F.R. §

1 201.57(c)(2)(iv) (requiring that “all indications listed in [the Indications and Usage] section [of the  
2 drug labeling] must be supported by substantial evidence of effectiveness based on adequate and well-  
3 controlled studies as defined in § 314.126(b),” where § 314.126(b) provides placebo concurrent control,  
4 dose-comparison concurrent control, and active treatment concurrent control as examples).

5 86. Upon information and belief, the only FDA-approved indication for fingolimod, and the  
6 only indication adequately supported by adequate tests and studies, is the same as that of Novartis’s  
7 GILENYA<sup>®</sup> product and that recited in at least claim 1 of the ’179 patent, specifically the treatment of  
8 relapsing-remitting multiple sclerosis.

9 87. Thus, upon information and belief, Handa’s 505(b)(2) NDA Product labeling will  
10 disclose all elements of at least claim 1 of the ’179 patent, therefore showing that use by, for example,  
11 patients and/or healthcare providers of Handa’s 505(b)(2) NDA Product in accordance with its  
12 proposed labeling will infringe at least claim 1 of the ’179 patent.

13 88. Upon information and belief, Handa’s 505(b)(2) NDA Product’s proposed labeling will  
14 instruct, for example, patients and/or healthcare providers to perform all elements of at least claim 1 of  
15 the ’179 patent.

16 89. The commercial manufacture, use, offer for sale, sale, marketing, distributing, and/or  
17 importation of Handa’s 505(b)(2) NDA Product would infringe one or more claims of the ’179 patent.

18 90. Upon information and belief, use of Handa’s 505(b)(2) NDA Product in accordance  
19 with and as directed by its proposed labeling would infringe one or more claims of the ’179 patent.

20 91. Upon information and belief, Handa will have actual knowledge of the ’179 patent and  
21 will actively induce infringement of the ’179 patent when its 505(b)(2) NDA is approved, and will do  
22 so immediately and imminently upon final approval.

23 92. Upon information and belief, Handa will know that its 505(b)(2) NDA Product is  
24 especially made or adapted for use in infringing the ’179 patent, and that its 505(b)(2) NDA Product is  
25 not suitable for any substantial non-infringing use. Upon information and belief, Handa will contribute  
26 to the infringement of the ’179 patent immediately and imminently upon approval of its 505(b)(2)  
27 NDA.

28

1 93. The foregoing acts by Handa constitute and/or will constitute active inducement of  
2 infringement of the '179 patent and/or contribution to the infringement by others of the '179 patent  
3 under 35 U.S.C. §§ 271(b) and (c).

4 94. If Handa's infringement of the '179 patent is not permanently enjoined, Plaintiff will  
5 suffer substantial and irreparable harm for which there is no remedy at law.

6 **COUNT IV: DECLARATORY JUDGMENT OF INFRINGEMENT BY EACH DEFENDANT**  
7 **OF THE '179 PATENT UNDER 35 U.S.C. §§ 271(b) AND (c)**

8 95. Plaintiff incorporates each of the preceding paragraphs 1 – 94 as if fully set forth herein.

9 96. Upon information and belief, Handa intends to engage in the commercial manufacture,  
10 use, offer for sale, sale, marketing, distributing, and/or importation of its 505(b)(2) NDA Product with  
11 its proposed labeling immediately and imminently upon final approval of its 505(b)(2) NDA.  
12 Therefore a case or controversy exists between each Defendant or group of Defendants and Novartis  
13 as to infringement of the '179 patent.

14 97. Handa, by filing its 505(b)(2) NDA, has represented to the FDA that, upon approval, its  
15 505(b)(2) NDA Product will have the same active ingredient or a pharmaceutically acceptable salt  
16 thereof and dosage amount as GILENYA<sup>®</sup>, and will be bioequivalent to GILENYA<sup>®</sup>. Specifically,  
17 Handa has indicated to Novartis that its 505(b)(2) NDA Product contains the same drug in the same  
18 dosage amount as GILENYA<sup>®</sup>, and that Handa's 505(b)(2) NDA contains the bioavailability and/or  
19 bioequivalence data and information from studies of Handa's 505(b)(2) NDA Product.

20 98. Handa has indicated that its 505(b)(2) NDA Product is orally administered and contains  
21 0.5 mg fingolimod.

22 99. FDA regulations require that Handa's 505(b)(2) NDA Product labeling contain safety  
23 information associated with its 505(b)(2) NDA Product. *See* 21 C.F.R. 201.56(a)(1) ("The labeling  
24 must contain a summary of the essential scientific information needed for the safe and effective use of  
25 the drug."); 21 C.F.R. 201.57(c)(6) (requiring under "Warnings and precautions" a description of  
26 "clinically significant adverse reactions (including any that are potentially fatal, are serious even if  
27 infrequent, or can be prevented or mitigated through appropriate use of the drug), other potential safety  
28 hazards [], limitations in use imposed by them [], and steps that should be taken if they occur[.]")

1           100. As reflected in the GILENYA<sup>®</sup> label (attached hereto as **Exhibit C**) under the heading  
2 “WARNINGS AND PRECAUTIONS” and further under the heading “Infections,” FDA has required  
3 instruction that “[p]atients without a healthcare professional confirmed history of chickenpox or  
4 without documentation of a full course of vaccination against VZV should be tested for antibodies to  
5 VZV before initiating GILENYA” and furthermore that “VZV vaccination of antibody-negative  
6 patients is recommended prior to commencing treatment with GILENYA.” Upon information and  
7 belief, Handa’s 505(b)(2) NDA proposed labeling contains an identical or substantially similar  
8 instruction.

9           101. FDA regulations require that Handa’s 505(b)(2) NDA Product labeling instruct that its  
10 505(b)(2) NDA Product be administered for approved indications at approved dosages. *See* 21 U.S.C.  
11 § 355(d) (setting forth that FDA may reject an NDA that does not contain reports showing “adequate  
12 tests by all methods reasonably applicable to show whether or not [the] drug is safe for use under the  
13 conditions prescribed, recommended, or suggested in the proposed labeling thereof”); 21 C.F.R. §  
14 201.57(c)(2)(iv) (requiring that “all indications listed in [the Indications and Usage] section [of the  
15 drug labeling] must be supported by substantial evidence of effectiveness based on adequate and well-  
16 controlled studies as defined in § 314.126(b),” where § 314.126(b) provides placebo concurrent control,  
17 dose-comparison concurrent control, and active treatment concurrent control as examples).

18           102. Upon information and belief, the only FDA-approved indication for fingolimod, and the  
19 only indication adequately supported by adequate tests and studies, is the same as that of Novartis’s  
20 GILENYA<sup>®</sup> product and that recited in at least claim 1 of the ’179 patent, specifically the treatment of  
21 relapsing-remitting multiple sclerosis.

22           103. Thus, upon information and belief, Handa’s 505(b)(2) NDA Product labeling will  
23 disclose all elements of at least claim 1 of the ’179 patent, therefore showing that use by, for example,  
24 patients and/or healthcare providers of Handa’s 505(b)(2) NDA Product in accordance with its  
25 proposed labeling will infringe at least claim 1 of the ’179 patent.

26           104. Upon information and belief, Handa’s 505(b)(2) NDA Product’s proposed labeling will  
27 instruct, for example, patients and/or healthcare providers to perform all elements of at least claim 1 of  
28 the ’179 patent.



1 105. The commercial manufacture, use, offer for sale, sale, marketing, distributing, and/or  
2 importation of Handa's 505(b)(2) NDA Product would infringe one or more claims of the '179 patent.

3 106. Upon information and belief, use of Handa's 505(b)(2) NDA Product in accordance  
4 with and as directed by its proposed labeling would infringe one or more claims of the '179 patent.

5 107. Upon information and belief, Handa will have actual knowledge of the '179 patent and  
6 will actively induce infringement of the '179 patent when its 505(b)(2) NDA is approved, and will do  
7 so immediately and imminently upon final approval.

8 108. Upon information and belief, Handa will know that its 505(b)(2) NDA Product is  
9 especially made or adapted for use in infringing the '179 patent, and that its 505(b)(2) NDA Product is  
10 not suitable for any substantial non-infringing use. Upon information and belief, Handa will contribute  
11 to the infringement of the '179 patent immediately and imminently upon approval of its 505(b)(2)  
12 NDA.

13 109. The foregoing acts by Handa constitute and/or will constitute active inducement of  
14 infringement of the '179 patent and/or contribution to the infringement by others of the '179 patent  
15 under 35 U.S.C. §§ 271(b) and (c).

16 110. If Handa's infringement of the '179 patent is not permanently enjoined, Plaintiff will  
17 suffer substantial and irreparable harm for which there is no remedy at law.

18 **PRAYER FOR RELIEF**

19 WHEREFORE, Novartis prays that this Court grant the following relief:

- 20 a. A declaration that Handa's imminent making, using, offering to sell, or selling in the  
21 United States, or importing into the United States, or inducing or contributing to the  
22 same, of its 505(b)(2) NDA Product will infringe the '405 patent;
- 23 b. A judgment that one or more claims of the '405 patent is not invalid, is not  
24 unenforceable, and is infringed Handa's 505(b)(2) NDA submission, and that Handa's  
25 making, using, offering to sell, or selling in the United States, or importing into the  
26 United States of its 505(b)(2) NDA Product will infringe the '405 patent;
- 27 c. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any  
28 approval of Handa's 505(b)(2) NDA shall be a date not earlier than the expiration date

1 of the '405 patent, including any extensions and/or additional periods of exclusivity to  
2 which Novartis is or becomes entitled;

3 d. An order enjoining Handa, its affiliates, subsidiaries, and each of its officers, agents,  
4 servants, and employees and those acting in privity or in concert with Handa, from  
5 making, using, offering to sell, or selling in the United States, or importing into the  
6 United States its 505(b)(2) NDA Product, until after the expiration date of the '405  
7 patent, including any extensions and/or additional periods of exclusivity to which  
8 Novartis is or becomes entitled;

9 e. Damages, including monetary and other relief, to Novartis if Handa engages in  
10 commercial manufacture, use, offers to sell, sale, or importation in or into the United  
11 States of its 505(b)(2) NDA Product, prior to the expiration date of the '405 patent,  
12 including any extensions and/or additional periods of exclusivity to which Novartis is  
13 or becomes entitled;

14 f. A declaration that Handa's imminent making, using, offering to sell, or selling in the  
15 United States, or importing into the United States, or inducing or contributing to the  
16 same, of its 505(b)(2) NDA ProductProduct will infringe the '179 patent;

17 g. A judgment that one or more claims of the '179 patent is not invalid, is not  
18 unenforceable, and is infringed by Handa's 505(b)(2) NDA submission, and that  
19 Handa's making, using, offering to sell, or selling in the United States, or importing into  
20 the United States of its 505(b)(2) NDA Product will infringe the '179 patent;

21 h. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any  
22 approval of Handa's 505(b)(2) NDA shall be a date not earlier than the expiration date  
23 of the '179 patent, including any extensions and/or additional periods of exclusivity to  
24 which Novartis is or becomes entitled;

25 i. An order enjoining Handa, its affiliates, subsidiaries, and each of its officers, agents,  
26 servants, and employees and those acting in privity or in concert with Handa, from  
27 making, using, offering to sell, or selling in the United States, or importing into the  
28 United States its 505(b)(2) NDA Product, until after the expiration date of the '179

1 patent, including any extensions and/or additional periods of exclusivity to which  
2 Novartis is or becomes entitled;

3 j. Damages, including monetary and other relief, to Novartis if Handa engages in  
4 commercial manufacture, use, offers to sell, sale, or importation in or into the United  
5 States of its 505(b)(2) NDA Product, prior to the expiration date of the '179 patent,  
6 including any extensions and/or additional periods of exclusivity to which Novartis is  
7 or becomes entitled;

8 k. Such further and other relief as this Court deems proper and just, including any  
9 appropriate relief under 35 U.S.C. § 285.

11 Respectfully Submitted,

12 Dated: May 6, 2021

/s/ Y. Ernest Hsin

13 Y. Ernest Hsin (CA Bar No. 201668)  
14 *ehsin@gibsondunn.com*  
15 GIBSON, DUNN & CRUTCHER LLP  
16 555 Mission Street  
17 San Francisco, CA 94105  
18 Telephone: 415.393.8200  
19 Facsimile: 415.393.8306

20 Jane M Love, Ph.D. (*pro hac vice* to be filed)  
21 (NY Bar No. 3016995)  
22 *jlove@gibsondunn.com*  
23 Robert W. Trenchard (*pro hac vice* to be filed)  
24 (NY Bar No. 2679488)  
25 *rtrenchard@gibsondunn.com*  
26 GIBSON, DUNN & CRUTCHER LLP  
27 200 Park Ave  
28 New York, NY 10166  
Telephone: 212.351.4000  
Facsimile: 212.351.4035

Christine L. Ranney (CA Bar No. 295773)  
*cranney@gibsondunn.com*  
GIBSON, DUNN & CRUTCHER LLP  
1801 California St.  
Denver, CO 80202  
Telephone: 303.298.5700  
Facsimile: 303.298.5907

*Attorneys for Plaintiff*  
*Novartis Pharmaceuticals Corporation*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28